Abstract
We have reported that increasing the length of infusion from 5 min to 1 h appeared to substantially reduce the toxicity associated with fluorouracil (5-FU) modulated by leucovorin (LV) and interferon α-2a (IFN-α). This phase II study assessed the antitumor efficacy of this regimen. Patients (n=38) with colorectal cancer received IFN-α 5 MU/m2 SC on days 1-6; on days 2-6, LV 200 mg/m2 IV was given with 5-FU at initial doses of 370-425 mg/m2/h. The regimen was well-tolerated with no grade 4 toxicity. At 425 mg/m2 5-FU, grade 3 toxicities included diarrhea (8.6%), anorexia, fever and fatigue (5.7% each), neutropenia and nausea/vomiting (2.9% each). Individuals tolerated 5-FU doses up to 644 mg/m2. Objective responses occurred in 27% of 37 patients; median time to progression and survival were 6.1 and 12.9 months. Only 1 of 25 informative tumor samples had high-frequency microsatellite instability (MSI), while 7 of 23 assessable patients (30%) with MSI-negative tumors had an objective response. With 425 mg/m2, the average 5-FU Cp and AUC 0-1 h were 37.4 μM and 1161 μM/h. Some 6 patients had extended sampling, and the half-lives of 5-FU and FBAL (apparent) were 8.6 and 100.0 min, respectively. A 1-h infusion of 5-FU is well tolerated; individual dose escalation of 5-FU allows each patient to receive the maximum tolerable dose.
Original language | English (US) |
---|---|
Pages (from-to) | 1145-1152 |
Number of pages | 8 |
Journal | Oncology reports |
Volume | 13 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2005 |
Externally published | Yes |
Keywords
- Adenocarcinoma
- Fluorouracil
- Interferon α-2a
- Large bowel
- Leucovorin
ASJC Scopus subject areas
- Oncology
- Cancer Research